SMER28 | CAS#307538-42-7 | autophagy

MedKoo Cat#: 526824 | Name: SMER28

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SMER28 is a small molecule modulator of autophagy, inducing autophagy independently of rapamycin in mammalian cells. SMER28, acting via an mTOR-independent mechanism, prevented the accumulation of amyloid beta peptide within these cells. SMER28 may have therapeutic potential for the treatment of Alzheimer's disease and other proteinopathies.

Chemical Structure

SMER28

CAS#307538-42-7

Theoretical Analysis

MedKoo Cat#: 526824

Name: SMER28

CAS#: 307538-42-7

Chemical Formula: C11H10BrN3

Exact Mass: 263.0058

Molecular Weight: 264.13

Elemental Analysis: C, 50.02; H, 3.82; Br, 30.25; N, 15.91

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,450.00	2 Weeks
1g	USD 3,450.00	2 Weeks
2g	USD 5,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SMER28; SMER-28; SMER 28.

IUPAC/Chemical Name

6-bromo-N-2-propen-1-yl-4-quinazolinamine

InChi Key

BCPOLXUSCUFDGE-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H10BrN3/c1-2-5-13-11-9-6-8(12)3-4-10(9)14-7-15-11/h2-4,6-7H,1,5H2,(H,13,14,15)

SMILES Code

C=CCNC1=C2C=C(Br)C=CC2=NC=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SMER28 is a positive regulator of autophagy acting via an mTOR-independent mechanism. SMER28 prevents the accumulation of amyloid beta peptide.

In vitro activity:

SMER28 has a unique spectrum of bioactivities distinct from other known microtubule-stabilizing or autophagy-inducing drugs. In cells, SMER28 significantly stabilized microtubules and decelerated microtubule dynamics. SMER28 displayed neurotrophic and neuroprotective effects at the cellular level by inducing neurite outgrowth and protecting from excitotoxin-induced axon degeneration. Reference: Sci Rep. 2022 Oct 25;12(1):17805. https://pubmed.ncbi.nlm.nih.gov/36284196/

In vivo activity:

SMER28 has potential in facilitating the safe administration of higher radiation doses and improving the cure rates of radiotherapy for cancer patients. This study found that SMER28 protected mouse bone marrow and liver against radiation damage and facilitated survival of mice after lethal whole body or abdominal irradiation. Reference: Invest New Drugs. 2018 Oct;36(5):773-781. https://pubmed.ncbi.nlm.nih.gov/29387992/

	Solvent	mg/mL	mM
Solubility
	DMF	1.0	3.79
	DMSO	30.0	113.58
	Ethanol	30.0	113.58

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 264.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kirchenwitz M, Stahnke S, Grunau K, Melcher L, van Ham M, Rottner K, Steffen A, Stradal TEB. The autophagy inducer SMER28 attenuates microtubule dynamics mediating neuroprotection. Sci Rep. 2022 Oct 25;12(1):17805. doi: 10.1038/s41598-022-20563-3. PMID: 36284196; PMCID: PMC9596692. 2. Kirchenwitz M, Stahnke S, Prettin S, Borowiak M, Menke L, Sieben C, Birchmeier C, Rottner K, Stradal TEB, Steffen A. SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta. Cells. 2022 May 16;11(10):1648. doi: 10.3390/cells11101648. PMID: 35626685; PMCID: PMC9140127. 3. Koukourakis MI, Giatromanolaki A, Fylaktakidou K, Sivridis E, Zois CE, Kalamida D, Mitrakas A, Pouliliou S, Karagounis IV, Simopoulos K, Ferguson DJP, Harris AL. SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Invest New Drugs. 2018 Oct;36(5):773-781. doi: 10.1007/s10637-018-0566-0. Epub 2018 Jan 31. PMID: 29387992. 4. Doulatov S, Vo LT, Macari ER, Wahlster L, Kinney MA, Taylor AM, Barragan J, Gupta M, McGrath K, Lee HY, Humphries JM, DeVine A, Narla A, Alter BP, Beggs AH, Agarwal S, Ebert BL, Gazda HT, Lodish HF, Sieff CA, Schlaeger TM, Zon LI, Daley GQ. Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Sci Transl Med. 2017 Feb 8;9(376):eaah5645. doi: 10.1126/scitranslmed.aah5645. PMID: 28179501; PMCID: PMC5501179.

In vitro protocol:

In vivo protocol:

1. Koukourakis MI, Giatromanolaki A, Fylaktakidou K, Sivridis E, Zois CE, Kalamida D, Mitrakas A, Pouliliou S, Karagounis IV, Simopoulos K, Ferguson DJP, Harris AL. SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Invest New Drugs. 2018 Oct;36(5):773-781. doi: 10.1007/s10637-018-0566-0. Epub 2018 Jan 31. PMID: 29387992. 2. Doulatov S, Vo LT, Macari ER, Wahlster L, Kinney MA, Taylor AM, Barragan J, Gupta M, McGrath K, Lee HY, Humphries JM, DeVine A, Narla A, Alter BP, Beggs AH, Agarwal S, Ebert BL, Gazda HT, Lodish HF, Sieff CA, Schlaeger TM, Zon LI, Daley GQ. Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Sci Transl Med. 2017 Feb 8;9(376):eaah5645. doi: 10.1126/scitranslmed.aah5645. PMID: 28179501; PMCID: PMC5501179.

1: Rosenthal AK, Gohr CM, Mitton-Fitzgerald E, Grewal R, Ninomiya J, Coyne CB, Jackson WT. Autophagy modulates articular cartilage vesicle formation in primary articular chondrocytes. J Biol Chem. 2015 May 22;290(21):13028-38. doi: 10.1074/jbc.M114.630558. Epub 2015 Apr 13. PubMed PMID: 25869133; PubMed Central PMCID: PMC4505557. 2: Kalamida D, Karagounis IV, Giatromanolaki A, Koukourakis MI. Important role of autophagy in endothelial cell response to ionizing radiation. PLoS One. 2014 Jul 10;9(7):e102408. doi: 10.1371/journal.pone.0102408. eCollection 2014. PubMed PMID: 25010689; PubMed Central PMCID: PMC4092133. 3: Tian Y, Chang JC, Greengard P, Flajolet M. The convergence of endosomal and autophagosomal pathways: implications for APP-CTF degradation. Autophagy. 2014 Apr;10(4):694-6. doi: 10.4161/auto.27802. Epub 2014 Jan 16. PubMed PMID: 24447917; PubMed Central PMCID: PMC4091156. 4: Tian Y, Bustos V, Flajolet M, Greengard P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 2011 Jun;25(6):1934-42. doi: 10.1096/fj.10-175158. Epub 2011 Mar 2. PubMed PMID: 21368103; PubMed Central PMCID: PMC3101026. 5: Shen D, Coleman J, Chan E, Nicholson TP, Dai L, Sheppard PW, Patton WF. Novel cell- and tissue-based assays for detecting misfolded and aggregated protein accumulation within aggresomes and inclusion bodies. Cell Biochem Biophys. 2011 Jul;60(3):173-85. doi: 10.1007/s12013-010-9138-4. PubMed PMID: 21132543; PubMed Central PMCID: PMC3112480.